ClinicalTrials.gg
RecruitingNCT07309718Updated Dec 30, 2025

MPR for Stroke Risk Assessment of ICAS

An observational study in ICAS - Intracranial Atherosclerosis, Stroke Ischemic and Hemodynamic, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Xuanwu Hospital, Beijing · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Intracranial Arteriosclerosis with a site in China — 28 open to participants now, 28 under way, 2 of them phase 3. Intracranial Arteriosclerosis · China.

Planned enrollment
6th of 17
400 · median 300
Started
2025
with 2 others
Observational
17 of 44
12 open now
Primary completion
2027-12
later than 21 of 27 live
Registered
40th of 44
by date
Lead sponsor
6 of 44
Xuanwu Hospital, Beijing

Among the 44 studies in Intracranial Arteriosclerosis with a site in China, this one is the 6th largest by planned enrollment of the 17 observational ones that give a count, is one of 3 that started in 2025, is one of 17 observational ones, reaches primary completion later than 21 of the 27 other live ones, and was the 40th registered.

Intracranial Arteriosclerosis

103 studies on the registry are indexed under Intracranial Arteriosclerosis; 49 are open to participants now.

Browse Intracranial Arteriosclerosis studies →

Open to participants now

28 of the 44 studies in Intracranial Arteriosclerosis with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Intracranial Arteriosclerosis studies recruiting now, 12 (41%) set no upper age limit and 1 (3%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Intracranial Arteriosclerosis with a site in China, or all of them as a file.
02

Study summary

Intracranial atherosclerotic stenosis (ICAS) carries substantial stroke risk despite optimal medical treatment. Current risk stratification relies primarily on stenosis severity, but novel hemodynamic markers may improve prediction. In this multiple prospective registry study we aim to investigate whether regional hemodynamics, measured by a novel Magnetic resonance imaging-derived Pressure Ratio (MPR) technique, are associated with stroke risk in ICAS.

Read the detailed description

This study is a multicentre prospective single-arm registry study and the protocol is approved by the ethics committee at the coordinating centre and by the local institutional review board at each participating centre. This study is initiated by the investigators, with 5 participating stroke centres , and plans to recruit 400 consecutive patients who meet the inclusion and exclusion criteria. After the enrolment, all participants would be evaluated at baseline, 1 month, 6 months, and 12 months post-enrollment. All participants received standardized medical therapy, including dual antiplatelet treatment and management of vascular risk factors, in accordance with AHA/ASA guidelines. Multimodal imaging techniques were employed to assess hemodynamic status: luminal stenosis would be evaluated using transcranial Doppler (TCD), computed tomography angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA), high-resolution MRI and phase-contrast MR angiography (PC-MRA) would be collected to calculate MPR. The primary outcomes were ischemic stroke in the qualifying artery territory or related death within 1 year. There were 5 secondary outcomes, including hemodynamic ischemic stroke in the qualifying artery territory within1 year. An independent Data and Safety Monitoring Board (DSMB) oversees the conduction, safety and efficacy of the study.

03

Conditions studied

  • ICAS - Intracranial Atherosclerosis
  • Stroke Ischemic
  • Hemodynamic

Keywords

  • ICAS - Intracranial Atherosclerosis
  • Stroke Ischemic
  • Hemodynamic
  • Pressure ratio
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with ICAS involving 50% to 99% stenosis of a major intracranial artery in the anterior circulation, including the internal carotid artery (ICA C6-C7 segment) and the middle cerebral artery M1 (MCA-M1) segment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 to 80 years.
  2. Intracranial atherosclerotic stenosis ICAS involving a culprit artery in the anterior circulation.
  3. Intracranial arterial stenosis of 50% to 99% as measured by the WASID method using TCD, CTA, MRA, or DSA.
  4. Written obtained from the participant or a legal representative.

Exclusion criteria

Exclusion Criteria:

  1. Non-atherosclerotic intracranial lesions, including moyamoya disease, vasculitis, vascular dissection, diseases, or congenital/genetic abnormalities.
  2. More than 50% stenosis of the extracranial carotid artery on the ipsilateral side.
  3. Large cerebral infarction involving more than one-half of the territory on DWI imaging, or a baseline modified Rankin Scale score ≥3.
  4. to antiplatelet therapy or statins.
  5. Inability to undergo MRI due to metal implants or claustrophobia.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • CASSISS-MPR

    Drug: Standardized medical therapy targeting vascular risk factors and stroke prevention

Interventions

  • DrugStandardized medical therapy targeting vascular risk factors and stroke prevention

    Dual antiplatelet treatment and management of vascular risk factors, in accordance with AHA/ASA guidelines

06

What researchers measure

Primary outcomes

  1. ischemic stroke in the qualifying artery territory or related death within 1 year after enrollment.

    the number of participants who suffer from ischemic stroke in the qualifying artery territory or related death within 1 year after enrollment.

    Time frame: 12 months

Secondary outcomes

  1. transient ischemic attack (TIA) or ischemic stroke in the qualifying artery territory within 1 year

    the number of participants who suffer from transient ischemic attack (TIA) or ischemic stroke in the qualifying artery territory within 1 year after enrollment.

    Time frame: 12 months

  2. TIA related to ischemia in the qualifying artery territory within 1 year

    the number of participants who suffer from TIA related to ischemia in the qualifying artery territory within 1 year

    Time frame: 12 months

  3. any stroke/TIA/ death within 1 year

    the number of participants who suffer from any stroke/TIA/ death within 1 year

    Time frame: 12 months

  4. hemodynamic ischemic stroke in the qualifying artery territory within 1 year

    the number of participants who suffer from hemodynamic ischemic stroke in the qualifying artery territory within 1 year

    Time frame: 12 months

  5. embolic stroke within in the qualifying artery territory 1 year

    the number of participants who suffer from embolic stroke within in the qualifying artery territory 1 year

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Department of Neurosurgery, Xuanwu hospital
    Beijing, Xicheng District 100053, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 30, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Dec 15, 2027
CompletionEst.
Mar 31, 2028
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07309718
Collaborators
Xuanwu Hebei Hospital, Xuanwu Xiongan Hospital, Xuanwu Chifeng Hospital, Xuanwu Jinan Hospital
Responsible party
Sponsor
First posted
Dec 30, 2025
Start date
Dec 1, 2025
Primary completion
Dec 15, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Dec 30, 2025

Study contacts

Jichang Luo, M.D.
Contact
luojichang_dr@sina.com
+86 13120136577

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion